JAK Inhibitors

At the moment we have been given a new therapeutic option for patients who do not respond to TNF inhibitors - Przemyslaw J. Kotyla

JAK Inhibitors

image by: BJC Health - Connected Care

HWN Recommends

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors

Since the end of the last century, biological therapies have taken the rheumatoid arthritis (RA) pharmaceutical market by storm. Anti-TNFs were launched in the late 1990’s and have rapidly become worldwide brands. Within a decade, Humira was the highest earning product across the entire market.

The success of biologics was defined by their comparable high efficacy over traditional therapeutic agents. This was primarily driven by advances in specific target selectivity. Older treatments such as methotrexate and corticosteroids are comparatively blunt tools, with a myriad of effects across the immune system and dose limiting toxicity. Treatment with biologics has led to a seismic shift…

read full article


 The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors

The past decade has witnessed an explosion in trial data on JAK inhibitors (JAKi). These small molecules target the Janus kinase - signal transducer and activator of transcription (JAK-STAT) pathway, blocking crucial cytokines across a septum of rheumatic diseases.


For the treatment of intermediate and high risk myelofibrosis. For the treatment of acute graft-versus-host (GVHD) not responsive steroids, in adults and pediatric patients 12 years of older.

Introducing Stitches!

Your Path to Meaningful Connections in the World of Health and Medicine
Connect, Collaborate, and Engage!

Coming Soon - Stitches, the innovative chat app from the creators of HWN. Join meaningful conversations on health and medical topics. Share text, images, and videos seamlessly. Connect directly within HWN's topic pages and articles.

Be the first to know when Stitches starts accepting users

Health Cloud

Stay Connected